Debashis Ghosh
Concepts (865)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gene Expression Profiling | 56 | 2025 | 1790 | 4.810 |
Why?
| | Leishmaniasis, Visceral | 18 | 2026 | 24 | 4.630 |
Why?
| | Data Interpretation, Statistical | 28 | 2020 | 365 | 4.350 |
Why?
| | Models, Statistical | 44 | 2024 | 667 | 4.270 |
Why?
| | Algorithms | 42 | 2026 | 1843 | 3.930 |
Why?
| | Oligonucleotide Array Sequence Analysis | 38 | 2016 | 751 | 3.220 |
Why?
| | Computational Biology | 21 | 2025 | 675 | 2.590 |
Why?
| | Computer Simulation | 36 | 2024 | 1014 | 2.510 |
Why?
| | Machine Learning | 10 | 2024 | 590 | 2.420 |
Why?
| | Psychodidae | 7 | 2023 | 8 | 2.120 |
Why?
| | Biomarkers, Tumor | 25 | 2022 | 1334 | 2.070 |
Why?
| | Metabolomics | 9 | 2022 | 737 | 2.020 |
Why?
| | Biometry | 13 | 2011 | 66 | 2.000 |
Why?
| | Software | 16 | 2025 | 673 | 1.980 |
Why?
| | Prostatic Neoplasms | 28 | 2024 | 972 | 1.790 |
Why?
| | Retinol-Binding Proteins | 5 | 2016 | 17 | 1.670 |
Why?
| | Eye Proteins | 6 | 2016 | 93 | 1.610 |
Why?
| | Neoplasms | 25 | 2024 | 2944 | 1.550 |
Why?
| | Regression Analysis | 13 | 2021 | 994 | 1.390 |
Why?
| | Phlebotomus | 5 | 2023 | 5 | 1.380 |
Why?
| | Leishmaniasis, Cutaneous | 4 | 2024 | 14 | 1.370 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 4 | 2023 | 926 | 1.280 |
Why?
| | Genomics | 12 | 2024 | 851 | 1.260 |
Why?
| | Neoplasm Proteins | 12 | 2018 | 443 | 1.250 |
Why?
| | Models, Biological | 14 | 2021 | 1758 | 1.230 |
Why?
| | Gene Expression Regulation, Neoplastic | 24 | 2021 | 1429 | 1.210 |
Why?
| | Humans | 207 | 2026 | 145625 | 1.200 |
Why?
| | Proportional Hazards Models | 11 | 2023 | 1318 | 1.180 |
Why?
| | Image Processing, Computer-Assisted | 9 | 2026 | 774 | 1.180 |
Why?
| | Statistics, Nonparametric | 8 | 2019 | 423 | 1.080 |
Why?
| | Causality | 4 | 2022 | 128 | 1.070 |
Why?
| | Biomarkers | 14 | 2021 | 4329 | 1.070 |
Why?
| | Bangladesh | 15 | 2026 | 64 | 1.060 |
Why?
| | Databases, Factual | 12 | 2024 | 1481 | 1.060 |
Why?
| | Diagnostic Imaging | 2 | 2022 | 340 | 1.050 |
Why?
| | Insecticides | 4 | 2023 | 44 | 1.020 |
Why?
| | Biostatistics | 3 | 2014 | 19 | 1.010 |
Why?
| | Insect Control | 4 | 2023 | 18 | 1.010 |
Why?
| | Insect Vectors | 4 | 2023 | 39 | 1.000 |
Why?
| | Aromatase | 2 | 2019 | 37 | 0.950 |
Why?
| | Endemic Diseases | 2 | 2024 | 33 | 0.940 |
Why?
| | Survival Analysis | 12 | 2024 | 1372 | 0.940 |
Why?
| | Natural Gas | 1 | 2025 | 25 | 0.870 |
Why?
| | Meta-Analysis as Topic | 4 | 2014 | 173 | 0.870 |
Why?
| | Oil and Gas Fields | 1 | 2025 | 32 | 0.870 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2025 | 299 | 0.850 |
Why?
| | Tumor Microenvironment | 3 | 2023 | 745 | 0.830 |
Why?
| | Microscopy | 3 | 2023 | 147 | 0.820 |
Why?
| | Cognitive Dysfunction | 5 | 2026 | 479 | 0.820 |
Why?
| | Magnetoencephalography | 2 | 2021 | 161 | 0.810 |
Why?
| | Lung Neoplasms | 7 | 2023 | 2674 | 0.810 |
Why?
| | Leishmania donovani | 5 | 2022 | 12 | 0.800 |
Why?
| | Colonic Neoplasms | 2 | 2022 | 257 | 0.800 |
Why?
| | Histological Techniques | 1 | 2023 | 38 | 0.780 |
Why?
| | Environmental Exposure | 3 | 2025 | 578 | 0.770 |
Why?
| | Genetic Association Studies | 5 | 2019 | 376 | 0.750 |
Why?
| | Models, Genetic | 11 | 2019 | 537 | 0.750 |
Why?
| | Multivariate Analysis | 16 | 2022 | 1531 | 0.750 |
Why?
| | Sequence Analysis, RNA | 1 | 2025 | 441 | 0.740 |
Why?
| | Zebrafish Proteins | 2 | 2016 | 314 | 0.720 |
Why?
| | Pyrethrins | 1 | 2021 | 8 | 0.700 |
Why?
| | Single-Cell Analysis | 1 | 2025 | 366 | 0.700 |
Why?
| | Connectome | 2 | 2021 | 99 | 0.690 |
Why?
| | Mass Spectrometry | 6 | 2022 | 728 | 0.680 |
Why?
| | Phenotype | 14 | 2026 | 3186 | 0.680 |
Why?
| | Parkinsonian Disorders | 1 | 2021 | 43 | 0.670 |
Why?
| | Brain Mapping | 2 | 2021 | 540 | 0.660 |
Why?
| | Housing | 2 | 2021 | 141 | 0.660 |
Why?
| | Brain | 4 | 2024 | 2981 | 0.650 |
Why?
| | Endpoint Determination | 2 | 2011 | 84 | 0.640 |
Why?
| | Cluster Analysis | 12 | 2024 | 494 | 0.640 |
Why?
| | Nitriles | 1 | 2021 | 211 | 0.630 |
Why?
| | Propensity Score | 4 | 2018 | 370 | 0.620 |
Why?
| | Feasibility Studies | 2 | 2024 | 1125 | 0.600 |
Why?
| | Neuroendocrine Tumors | 4 | 2026 | 122 | 0.600 |
Why?
| | Clinical Trials as Topic | 4 | 2022 | 1062 | 0.590 |
Why?
| | Placenta | 2 | 2019 | 794 | 0.590 |
Why?
| | Databases, Genetic | 11 | 2021 | 239 | 0.590 |
Why?
| | Risk Assessment | 8 | 2020 | 3678 | 0.590 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 1 | 2020 | 121 | 0.580 |
Why?
| | Learning | 1 | 2023 | 446 | 0.580 |
Why?
| | HIV Infections | 9 | 2026 | 3210 | 0.580 |
Why?
| | High-Throughput Screening Assays | 2 | 2012 | 179 | 0.580 |
Why?
| | Genetic Variation | 4 | 2019 | 992 | 0.570 |
Why?
| | Quantitative Trait, Heritable | 2 | 2018 | 118 | 0.570 |
Why?
| | DNA Copy Number Variations | 2 | 2017 | 189 | 0.570 |
Why?
| | Metadata | 1 | 2018 | 17 | 0.560 |
Why?
| | Male | 80 | 2026 | 73014 | 0.540 |
Why?
| | Metabolome | 1 | 2021 | 390 | 0.530 |
Why?
| | Protein Conformation | 4 | 2015 | 914 | 0.530 |
Why?
| | Ki-67 Antigen | 3 | 2026 | 119 | 0.530 |
Why?
| | Logistic Models | 12 | 2020 | 2112 | 0.530 |
Why?
| | Glioma | 1 | 2022 | 425 | 0.520 |
Why?
| | Genome-Wide Association Study | 8 | 2026 | 1526 | 0.520 |
Why?
| | Cardiovascular Diseases | 5 | 2022 | 2218 | 0.520 |
Why?
| | Reproducibility of Results | 17 | 2021 | 3396 | 0.510 |
Why?
| | Transcriptome | 2 | 2023 | 1066 | 0.510 |
Why?
| | Epidemiologic Methods | 2 | 2007 | 91 | 0.500 |
Why?
| | Randomized Controlled Trials as Topic | 5 | 2021 | 1754 | 0.500 |
Why?
| | Immunohistochemistry | 11 | 2022 | 1709 | 0.500 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 2 | 2023 | 1194 | 0.480 |
Why?
| | Female | 66 | 2026 | 79080 | 0.470 |
Why?
| | Case-Control Studies | 11 | 2026 | 3633 | 0.460 |
Why?
| | High-Intensity Interval Training | 2 | 2026 | 45 | 0.460 |
Why?
| | Markov Chains | 7 | 2017 | 128 | 0.460 |
Why?
| | Sensitivity and Specificity | 12 | 2024 | 1992 | 0.450 |
Why?
| | Linear Models | 7 | 2018 | 847 | 0.450 |
Why?
| | Registries | 2 | 2024 | 2382 | 0.450 |
Why?
| | Cytochrome P-450 Enzyme System | 2 | 2016 | 163 | 0.440 |
Why?
| | Crystallography, X-Ray | 7 | 2019 | 477 | 0.440 |
Why?
| | Empirical Research | 2 | 2012 | 21 | 0.430 |
Why?
| | Bayes Theorem | 7 | 2022 | 424 | 0.420 |
Why?
| | Protein Folding | 1 | 2016 | 281 | 0.420 |
Why?
| | Carcinoma, Squamous Cell | 4 | 2017 | 627 | 0.420 |
Why?
| | Diagnosis, Computer-Assisted | 4 | 2008 | 91 | 0.410 |
Why?
| | Autism Spectrum Disorder | 2 | 2017 | 404 | 0.410 |
Why?
| | Lupus Nephritis | 2 | 2025 | 67 | 0.410 |
Why?
| | Statistics as Topic | 3 | 2025 | 277 | 0.400 |
Why?
| | Nerve Net | 3 | 2024 | 284 | 0.400 |
Why?
| | Protein Tyrosine Phosphatases | 3 | 2019 | 166 | 0.380 |
Why?
| | Bias | 5 | 2022 | 196 | 0.380 |
Why?
| | Spectrometry, Fluorescence | 4 | 2016 | 165 | 0.380 |
Why?
| | Treatment Outcome | 10 | 2026 | 11744 | 0.380 |
Why?
| | India | 6 | 2023 | 213 | 0.370 |
Why?
| | Disease Progression | 15 | 2021 | 2857 | 0.360 |
Why?
| | Tissue Array Analysis | 3 | 2008 | 49 | 0.360 |
Why?
| | Oncogenes | 1 | 2013 | 113 | 0.360 |
Why?
| | Herpes Zoster Vaccine | 2 | 2025 | 154 | 0.350 |
Why?
| | Sulfhydryl Compounds | 1 | 2014 | 189 | 0.350 |
Why?
| | Polymorphism, Single Nucleotide | 6 | 2026 | 2228 | 0.350 |
Why?
| | Middle Aged | 40 | 2026 | 36359 | 0.340 |
Why?
| | Animals | 33 | 2025 | 38030 | 0.340 |
Why?
| | Genome | 5 | 2017 | 307 | 0.340 |
Why?
| | Insecticide-Treated Bednets | 3 | 2021 | 7 | 0.330 |
Why?
| | Aged | 33 | 2026 | 26251 | 0.330 |
Why?
| | Nerve Tissue Proteins | 4 | 2023 | 594 | 0.330 |
Why?
| | Exercise Therapy | 2 | 2026 | 486 | 0.330 |
Why?
| | Colorado | 7 | 2026 | 4588 | 0.330 |
Why?
| | Cardiac Catheterization | 1 | 2015 | 569 | 0.330 |
Why?
| | Diabetes Mellitus, Type 2 | 3 | 2022 | 2623 | 0.330 |
Why?
| | Monocytes | 2 | 2025 | 538 | 0.320 |
Why?
| | Supervised Machine Learning | 2 | 2021 | 23 | 0.320 |
Why?
| | Herpes Zoster | 2 | 2025 | 318 | 0.310 |
Why?
| | Principal Component Analysis | 2 | 2023 | 192 | 0.310 |
Why?
| | Adenocarcinoma | 4 | 2017 | 927 | 0.310 |
Why?
| | Alzheimer Disease | 3 | 2015 | 640 | 0.310 |
Why?
| | Precision Medicine | 2 | 2025 | 462 | 0.310 |
Why?
| | Antioxidants | 1 | 2014 | 544 | 0.310 |
Why?
| | Gene Expression | 3 | 2014 | 1461 | 0.310 |
Why?
| | Models, Neurological | 2 | 2024 | 252 | 0.310 |
Why?
| | Child, Preschool | 9 | 2025 | 11888 | 0.300 |
Why?
| | Endoplasmic Reticulum | 1 | 2012 | 268 | 0.300 |
Why?
| | Stem Cells | 3 | 2020 | 612 | 0.300 |
Why?
| | Flow Cytometry | 3 | 2026 | 1160 | 0.290 |
Why?
| | Epidemiologic Research Design | 1 | 2009 | 25 | 0.290 |
Why?
| | Gene Dosage | 1 | 2010 | 146 | 0.290 |
Why?
| | Signal Transduction | 10 | 2025 | 5234 | 0.290 |
Why?
| | Chromatin Immunoprecipitation | 3 | 2017 | 138 | 0.280 |
Why?
| | Risk Factors | 14 | 2025 | 10840 | 0.280 |
Why?
| | Child | 16 | 2025 | 22638 | 0.280 |
Why?
| | Bone Marrow Transplantation | 2 | 2008 | 298 | 0.280 |
Why?
| | Protein Array Analysis | 8 | 2009 | 56 | 0.280 |
Why?
| | Carcinoma | 2 | 2007 | 225 | 0.280 |
Why?
| | Liver Neoplasms | 1 | 2015 | 774 | 0.270 |
Why?
| | Proteomics | 5 | 2009 | 1202 | 0.270 |
Why?
| | Racemases and Epimerases | 5 | 2006 | 11 | 0.270 |
Why?
| | Statistical Distributions | 1 | 2008 | 7 | 0.270 |
Why?
| | Probability | 3 | 2021 | 308 | 0.270 |
Why?
| | Chromosome Mapping | 6 | 2017 | 505 | 0.260 |
Why?
| | Pancreatic Neoplasms | 4 | 2026 | 944 | 0.260 |
Why?
| | Emigration and Immigration | 1 | 2008 | 66 | 0.260 |
Why?
| | Exercise | 3 | 2026 | 2206 | 0.260 |
Why?
| | DNA-Binding Proteins | 7 | 2018 | 1467 | 0.260 |
Why?
| | Adult | 29 | 2026 | 40821 | 0.260 |
Why?
| | Arrhythmias, Cardiac | 2 | 2020 | 358 | 0.260 |
Why?
| | DNA Methylation | 4 | 2023 | 721 | 0.250 |
Why?
| | Research Design | 5 | 2021 | 1139 | 0.250 |
Why?
| | Tumor Burden | 1 | 2008 | 326 | 0.240 |
Why?
| | Mendelian Randomization Analysis | 1 | 2026 | 68 | 0.240 |
Why?
| | Disease Eradication | 1 | 2026 | 9 | 0.240 |
Why?
| | Entropy | 2 | 2023 | 44 | 0.240 |
Why?
| | Proteome | 3 | 2007 | 520 | 0.240 |
Why?
| | Pancreas | 2 | 2020 | 342 | 0.240 |
Why?
| | Urinary Bladder Neoplasms | 2 | 2021 | 257 | 0.230 |
Why?
| | Monte Carlo Method | 4 | 2017 | 150 | 0.230 |
Why?
| | Diabetes Mellitus | 5 | 2022 | 1101 | 0.230 |
Why?
| | Triple Negative Breast Neoplasms | 2 | 2019 | 219 | 0.220 |
Why?
| | Cytomegalovirus | 1 | 2026 | 169 | 0.220 |
Why?
| | Interleukin-2 Receptor beta Subunit | 1 | 2025 | 23 | 0.220 |
Why?
| | Cell Proliferation | 5 | 2021 | 2497 | 0.220 |
Why?
| | High-Throughput Nucleotide Sequencing | 3 | 2025 | 538 | 0.220 |
Why?
| | Amino Acid Sequence | 3 | 2016 | 2088 | 0.220 |
Why?
| | False Positive Reactions | 4 | 2012 | 124 | 0.220 |
Why?
| | Neoplasm Staging | 6 | 2019 | 1486 | 0.220 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2025 | 109 | 0.210 |
Why?
| | Adolescent | 13 | 2026 | 22451 | 0.210 |
Why?
| | Cell Nucleus | 2 | 2019 | 584 | 0.210 |
Why?
| | Homeodomain Proteins | 4 | 2020 | 525 | 0.210 |
Why?
| | Replication Origin | 1 | 2004 | 17 | 0.210 |
Why?
| | Sarcopenia | 1 | 2026 | 92 | 0.210 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2025 | 176 | 0.210 |
Why?
| | Herpesvirus 3, Human | 2 | 2025 | 342 | 0.210 |
Why?
| | Coinfection | 1 | 2026 | 143 | 0.210 |
Why?
| | Cytomegalovirus Infections | 1 | 2026 | 203 | 0.210 |
Why?
| | Viral Nonstructural Proteins | 1 | 2024 | 64 | 0.210 |
Why?
| | Fever | 2 | 2023 | 320 | 0.210 |
Why?
| | Genetic Predisposition to Disease | 5 | 2023 | 2455 | 0.200 |
Why?
| | Weather | 1 | 2024 | 43 | 0.200 |
Why?
| | Magnetic Resonance Imaging | 5 | 2022 | 3917 | 0.200 |
Why?
| | Data Curation | 1 | 2024 | 21 | 0.200 |
Why?
| | Dengue Virus | 1 | 2024 | 62 | 0.200 |
Why?
| | Leukemia | 1 | 2006 | 246 | 0.200 |
Why?
| | Carrier Proteins | 2 | 2007 | 728 | 0.200 |
Why?
| | Antigens | 1 | 2005 | 350 | 0.200 |
Why?
| | Melanoma | 3 | 2005 | 764 | 0.200 |
Why?
| | Ligands | 2 | 2016 | 676 | 0.200 |
Why?
| | ROC Curve | 5 | 2020 | 613 | 0.200 |
Why?
| | Dengue | 1 | 2024 | 92 | 0.200 |
Why?
| | Sample Size | 3 | 2008 | 123 | 0.190 |
Why?
| | Cell Phone | 1 | 2024 | 83 | 0.190 |
Why?
| | Coculture Techniques | 1 | 2004 | 244 | 0.190 |
Why?
| | Histones | 4 | 2020 | 670 | 0.190 |
Why?
| | Common Variable Immunodeficiency | 1 | 2023 | 26 | 0.190 |
Why?
| | Staining and Labeling | 1 | 2023 | 148 | 0.190 |
Why?
| | Recurrence | 5 | 2023 | 1125 | 0.190 |
Why?
| | Transforming Growth Factor beta | 1 | 2025 | 466 | 0.190 |
Why?
| | Skin Diseases, Parasitic | 1 | 2022 | 3 | 0.190 |
Why?
| | Membrane Transport Proteins | 1 | 2004 | 153 | 0.190 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2019 | 1156 | 0.190 |
Why?
| | Carcinogens | 1 | 2003 | 111 | 0.190 |
Why?
| | Frailty | 1 | 2026 | 206 | 0.190 |
Why?
| | Neoplasms, Experimental | 1 | 2003 | 163 | 0.190 |
Why?
| | Organometallic Compounds | 1 | 2023 | 110 | 0.180 |
Why?
| | Emphysema | 1 | 2023 | 100 | 0.180 |
Why?
| | Young Adult | 12 | 2026 | 14240 | 0.180 |
Why?
| | Personality | 1 | 2004 | 132 | 0.180 |
Why?
| | DNA, Complementary | 4 | 2007 | 269 | 0.180 |
Why?
| | Retina | 2 | 2016 | 330 | 0.180 |
Why?
| | Biomedical Research | 2 | 2025 | 724 | 0.180 |
Why?
| | Body Composition | 1 | 2026 | 686 | 0.180 |
Why?
| | Parasites | 1 | 2022 | 44 | 0.180 |
Why?
| | Estrogens | 2 | 2019 | 364 | 0.180 |
Why?
| | Neuroimaging | 2 | 2015 | 306 | 0.180 |
Why?
| | Cross-Sectional Studies | 5 | 2026 | 5875 | 0.180 |
Why?
| | Social Determinants of Health | 1 | 2026 | 315 | 0.170 |
Why?
| | Social Stigma | 1 | 2024 | 174 | 0.170 |
Why?
| | Breast Neoplasms | 7 | 2014 | 2411 | 0.170 |
Why?
| | Promoter Regions, Genetic | 3 | 2009 | 1236 | 0.170 |
Why?
| | Construction Materials | 1 | 2021 | 18 | 0.170 |
Why?
| | Leishmania | 1 | 2021 | 3 | 0.170 |
Why?
| | Polymorphism, Genetic | 1 | 2004 | 611 | 0.170 |
Why?
| | Membrane Glycoproteins | 1 | 2004 | 495 | 0.170 |
Why?
| | Analysis of Variance | 4 | 2024 | 1293 | 0.170 |
Why?
| | Tomography, X-Ray Computed | 2 | 2023 | 2766 | 0.170 |
Why?
| | Brain Waves | 1 | 2021 | 45 | 0.170 |
Why?
| | Infant | 3 | 2024 | 10093 | 0.170 |
Why?
| | Head and Neck Neoplasms | 2 | 2017 | 563 | 0.170 |
Why?
| | Mutation, Missense | 2 | 2016 | 331 | 0.170 |
Why?
| | Autoantibodies | 5 | 2020 | 1498 | 0.170 |
Why?
| | Zebrafish | 2 | 2016 | 533 | 0.170 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 2 | 2019 | 195 | 0.160 |
Why?
| | Anxiety Disorders | 1 | 2004 | 351 | 0.160 |
Why?
| | Receptors, Androgen | 2 | 2021 | 149 | 0.160 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2023 | 240 | 0.160 |
Why?
| | Genotype | 8 | 2019 | 1866 | 0.160 |
Why?
| | Epilepsies, Partial | 1 | 2021 | 62 | 0.160 |
Why?
| | Amino Acid Motifs | 2 | 2019 | 217 | 0.160 |
Why?
| | Hyaluronan Receptors | 1 | 2021 | 105 | 0.160 |
Why?
| | Pulmonary Emphysema | 1 | 2023 | 276 | 0.160 |
Why?
| | Peptides | 4 | 2007 | 991 | 0.160 |
Why?
| | Lymphocytes | 2 | 2023 | 379 | 0.160 |
Why?
| | Epilepsy | 2 | 2021 | 397 | 0.160 |
Why?
| | Pattern Recognition, Automated | 4 | 2009 | 74 | 0.160 |
Why?
| | RNA, Messenger | 8 | 2024 | 2783 | 0.150 |
Why?
| | Mexican Americans | 3 | 2008 | 119 | 0.150 |
Why?
| | Radiography | 1 | 2022 | 856 | 0.150 |
Why?
| | Androgens | 3 | 2012 | 179 | 0.150 |
Why?
| | Exome | 2 | 2018 | 232 | 0.150 |
Why?
| | Phosphorylation | 3 | 2019 | 1717 | 0.150 |
Why?
| | Toll-Like Receptors | 1 | 2020 | 193 | 0.150 |
Why?
| | Protein Binding | 5 | 2019 | 2239 | 0.150 |
Why?
| | Tretinoin | 1 | 2020 | 114 | 0.150 |
Why?
| | Disease Reservoirs | 1 | 2019 | 27 | 0.150 |
Why?
| | Drug Resistant Epilepsy | 1 | 2021 | 144 | 0.150 |
Why?
| | Tandem Mass Spectrometry | 3 | 2014 | 574 | 0.150 |
Why?
| | Hospital Mortality | 1 | 2024 | 1037 | 0.150 |
Why?
| | Patient Acceptance of Health Care | 2 | 2024 | 880 | 0.140 |
Why?
| | Molecular Sequence Data | 4 | 2015 | 2835 | 0.140 |
Why?
| | Disease | 1 | 2019 | 97 | 0.140 |
Why?
| | Core Binding Factor Alpha 1 Subunit | 1 | 2019 | 45 | 0.140 |
Why?
| | Functional Neuroimaging | 1 | 2019 | 61 | 0.140 |
Why?
| | Bone Regeneration | 1 | 2019 | 28 | 0.140 |
Why?
| | Gene Expression Regulation | 4 | 2014 | 2591 | 0.140 |
Why?
| | Mice | 16 | 2025 | 18266 | 0.140 |
Why?
| | Disease Transmission, Infectious | 1 | 2019 | 69 | 0.140 |
Why?
| | Diet | 1 | 2026 | 1271 | 0.140 |
Why?
| | Prognosis | 11 | 2021 | 4331 | 0.140 |
Why?
| | Multiple Sclerosis | 1 | 2024 | 434 | 0.140 |
Why?
| | Radiology Information Systems | 1 | 2018 | 35 | 0.140 |
Why?
| | Pituitary Gland | 2 | 2009 | 148 | 0.140 |
Why?
| | Protein Structure, Tertiary | 3 | 2012 | 834 | 0.140 |
Why?
| | Precancerous Conditions | 1 | 2020 | 162 | 0.140 |
Why?
| | Pilot Projects | 2 | 2021 | 1878 | 0.140 |
Why?
| | Neoplasms, Second Primary | 1 | 2019 | 103 | 0.140 |
Why?
| | SOXB1 Transcription Factors | 1 | 2019 | 66 | 0.140 |
Why?
| | Genetic Markers | 3 | 2015 | 337 | 0.140 |
Why?
| | Small Molecule Libraries | 1 | 2019 | 113 | 0.140 |
Why?
| | Wilms Tumor | 1 | 2019 | 90 | 0.130 |
Why?
| | Nuclear Proteins | 2 | 2019 | 739 | 0.130 |
Why?
| | Artificial Intelligence | 3 | 2008 | 385 | 0.130 |
Why?
| | Molecular Diagnostic Techniques | 3 | 2024 | 104 | 0.130 |
Why?
| | Observational Studies as Topic | 1 | 2018 | 133 | 0.130 |
Why?
| | Longitudinal Studies | 5 | 2026 | 3005 | 0.130 |
Why?
| | Protein Phosphatase 2 | 1 | 2018 | 41 | 0.130 |
Why?
| | Intensive Care Units | 1 | 2024 | 923 | 0.130 |
Why?
| | RNA, Neoplasm | 1 | 2017 | 76 | 0.130 |
Why?
| | Time Factors | 6 | 2026 | 7079 | 0.130 |
Why?
| | CD24 Antigen | 1 | 2017 | 18 | 0.130 |
Why?
| | RNA, Small Interfering | 2 | 2019 | 630 | 0.130 |
Why?
| | Genes, Neoplasm | 3 | 2007 | 26 | 0.130 |
Why?
| | Pregnancy | 5 | 2019 | 7217 | 0.130 |
Why?
| | Clinical Laboratory Techniques | 1 | 2018 | 96 | 0.130 |
Why?
| | DNA, Neoplasm | 1 | 2017 | 160 | 0.130 |
Why?
| | Child Health | 1 | 2019 | 152 | 0.130 |
Why?
| | Epigenomics | 1 | 2017 | 123 | 0.130 |
Why?
| | Osteogenesis | 1 | 2019 | 204 | 0.120 |
Why?
| | Clinical Trials, Phase III as Topic | 3 | 2012 | 116 | 0.120 |
Why?
| | Up-Regulation | 2 | 2018 | 840 | 0.120 |
Why?
| | Neoplasm Metastasis | 6 | 2019 | 693 | 0.120 |
Why?
| | Beryllium | 1 | 2018 | 163 | 0.120 |
Why?
| | Transcription, Genetic | 7 | 2013 | 1429 | 0.120 |
Why?
| | Antley-Bixler Syndrome Phenotype | 1 | 2016 | 1 | 0.120 |
Why?
| | Calcium Compounds | 1 | 2016 | 5 | 0.120 |
Why?
| | Tachycardia, Ventricular | 1 | 2018 | 179 | 0.120 |
Why?
| | Chemoradiotherapy, Adjuvant | 1 | 2016 | 44 | 0.120 |
Why?
| | Induction Chemotherapy | 1 | 2017 | 87 | 0.120 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2018 | 157 | 0.120 |
Why?
| | Memory, Short-Term | 1 | 2019 | 272 | 0.120 |
Why?
| | Tumor Cells, Cultured | 5 | 2021 | 878 | 0.120 |
Why?
| | Anesthesia Department, Hospital | 1 | 2016 | 5 | 0.120 |
Why?
| | Normal Distribution | 2 | 2014 | 22 | 0.120 |
Why?
| | Nurse Anesthetists | 1 | 2016 | 7 | 0.120 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2019 | 295 | 0.120 |
Why?
| | Chromosome Aberrations | 2 | 2007 | 167 | 0.120 |
Why?
| | RNA, Viral | 2 | 2024 | 691 | 0.120 |
Why?
| | Salivary Gland Neoplasms | 1 | 2016 | 39 | 0.120 |
Why?
| | Mosquito Control | 1 | 2016 | 30 | 0.120 |
Why?
| | Models, Theoretical | 1 | 2020 | 558 | 0.120 |
Why?
| | Lung Diseases, Interstitial | 1 | 2023 | 677 | 0.120 |
Why?
| | Lymph Nodes | 1 | 2019 | 511 | 0.120 |
Why?
| | Oxides | 1 | 2016 | 47 | 0.120 |
Why?
| | Anus Neoplasms | 1 | 2016 | 33 | 0.120 |
Why?
| | Transcription Factors | 6 | 2017 | 1728 | 0.120 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2019 | 456 | 0.120 |
Why?
| | Health Services Research | 1 | 2019 | 389 | 0.120 |
Why?
| | ErbB Receptors | 2 | 2012 | 636 | 0.120 |
Why?
| | Respiratory Sounds | 2 | 2007 | 102 | 0.120 |
Why?
| | Transcriptional Activation | 1 | 2018 | 368 | 0.120 |
Why?
| | X-Ray Diffraction | 1 | 2016 | 76 | 0.120 |
Why?
| | Age Factors | 4 | 2026 | 3321 | 0.120 |
Why?
| | Anesthesia, Obstetrical | 1 | 2016 | 30 | 0.120 |
Why?
| | Endopeptidases | 1 | 2016 | 80 | 0.120 |
Why?
| | Analgesia, Obstetrical | 1 | 2016 | 33 | 0.120 |
Why?
| | Kaplan-Meier Estimate | 3 | 2017 | 959 | 0.120 |
Why?
| | Host-Pathogen Interactions | 1 | 2019 | 366 | 0.120 |
Why?
| | Anal Canal | 1 | 2016 | 101 | 0.110 |
Why?
| | B7-H1 Antigen | 1 | 2018 | 245 | 0.110 |
Why?
| | Heart Arrest | 1 | 2020 | 410 | 0.110 |
Why?
| | Cough | 2 | 2007 | 123 | 0.110 |
Why?
| | Berylliosis | 1 | 2018 | 204 | 0.110 |
Why?
| | Cell Transformation, Neoplastic | 4 | 2007 | 314 | 0.110 |
Why?
| | Insulin-Secreting Cells | 1 | 2020 | 393 | 0.110 |
Why?
| | Oleic Acid | 1 | 2015 | 40 | 0.110 |
Why?
| | Anesthesiologists | 1 | 2016 | 68 | 0.110 |
Why?
| | Proteolysis | 1 | 2016 | 174 | 0.110 |
Why?
| | Mutation | 2 | 2025 | 4082 | 0.110 |
Why?
| | Aged, 80 and over | 13 | 2022 | 8351 | 0.110 |
Why?
| | Antibodies, Viral | 3 | 2026 | 683 | 0.110 |
Why?
| | Air Pollution | 2 | 2017 | 314 | 0.110 |
Why?
| | Hypoglycemic Agents | 2 | 2021 | 1411 | 0.110 |
Why?
| | Parkinson Disease | 1 | 2021 | 614 | 0.110 |
Why?
| | Prevalence | 3 | 2026 | 2852 | 0.110 |
Why?
| | Risk | 1 | 2017 | 917 | 0.110 |
Why?
| | Schizophrenia | 1 | 2019 | 476 | 0.110 |
Why?
| | Hypocreales | 1 | 2014 | 8 | 0.110 |
Why?
| | Neoplastic Stem Cells | 1 | 2019 | 402 | 0.110 |
Why?
| | Kidney Neoplasms | 1 | 2019 | 417 | 0.110 |
Why?
| | Defibrillators, Implantable | 1 | 2018 | 393 | 0.110 |
Why?
| | Cell Differentiation | 2 | 2020 | 1979 | 0.100 |
Why?
| | Discriminant Analysis | 3 | 2020 | 35 | 0.100 |
Why?
| | Catalysis | 2 | 2012 | 304 | 0.100 |
Why?
| | Ants | 1 | 2014 | 27 | 0.100 |
Why?
| | Executive Function | 1 | 2019 | 461 | 0.100 |
Why?
| | Gastrointestinal Microbiome | 1 | 2022 | 767 | 0.100 |
Why?
| | Blood Glucose | 2 | 2022 | 2357 | 0.100 |
Why?
| | Metmyoglobin | 1 | 2014 | 1 | 0.100 |
Why?
| | Influenza Vaccines | 1 | 2019 | 541 | 0.100 |
Why?
| | Colorectal Neoplasms | 3 | 2012 | 870 | 0.100 |
Why?
| | Sulfonic Acids | 1 | 2014 | 14 | 0.100 |
Why?
| | Treatment Failure | 1 | 2015 | 358 | 0.100 |
Why?
| | Cancer Survivors | 1 | 2019 | 347 | 0.100 |
Why?
| | Chromatography, Ion Exchange | 1 | 2014 | 57 | 0.100 |
Why?
| | Chromatography, Affinity | 1 | 2014 | 82 | 0.100 |
Why?
| | Antiprotozoal Agents | 1 | 2013 | 15 | 0.100 |
Why?
| | Chromatography, Gel | 1 | 2014 | 131 | 0.100 |
Why?
| | Benzothiazoles | 1 | 2014 | 39 | 0.100 |
Why?
| | Amphotericin B | 1 | 2013 | 36 | 0.100 |
Why?
| | Free Radical Scavengers | 1 | 2014 | 81 | 0.100 |
Why?
| | Survival Rate | 4 | 2019 | 2078 | 0.100 |
Why?
| | Cell Line, Tumor | 7 | 2019 | 3538 | 0.100 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 2015 | 237 | 0.100 |
Why?
| | Vaccines, Synthetic | 2 | 2025 | 138 | 0.100 |
Why?
| | Odds Ratio | 3 | 2020 | 1070 | 0.100 |
Why?
| | Crystallization | 1 | 2014 | 131 | 0.100 |
Why?
| | Atrial Fibrillation | 1 | 2020 | 559 | 0.100 |
Why?
| | Brain Diseases | 1 | 2015 | 157 | 0.100 |
Why?
| | Trans-Activators | 3 | 2020 | 371 | 0.100 |
Why?
| | Embryonic Stem Cells | 1 | 2014 | 124 | 0.100 |
Why?
| | Resistance Training | 2 | 2026 | 185 | 0.100 |
Why?
| | Influenza, Human | 1 | 2019 | 634 | 0.090 |
Why?
| | Cohort Studies | 8 | 2017 | 6045 | 0.090 |
Why?
| | Follow-Up Studies | 5 | 2023 | 5397 | 0.090 |
Why?
| | Estradiol | 2 | 2014 | 517 | 0.090 |
Why?
| | Rhodium | 1 | 2012 | 2 | 0.090 |
Why?
| | Interleukin-2 | 2 | 2025 | 434 | 0.090 |
Why?
| | Mice, Inbred BALB C | 3 | 2019 | 1244 | 0.090 |
Why?
| | Androstadienes | 1 | 2012 | 77 | 0.090 |
Why?
| | Nucleic Acid Amplification Techniques | 2 | 2022 | 39 | 0.090 |
Why?
| | Influenza A Virus, H5N1 Subtype | 1 | 2011 | 10 | 0.090 |
Why?
| | Silver | 1 | 2012 | 35 | 0.090 |
Why?
| | Least-Squares Analysis | 2 | 2020 | 73 | 0.090 |
Why?
| | CD8-Positive T-Lymphocytes | 3 | 2025 | 929 | 0.090 |
Why?
| | Repressor Proteins | 2 | 2007 | 428 | 0.090 |
Why?
| | Positron-Emission Tomography | 2 | 2024 | 342 | 0.090 |
Why?
| | Gene Silencing | 3 | 2007 | 200 | 0.090 |
Why?
| | Transcription Factor Pit-1 | 1 | 2011 | 26 | 0.090 |
Why?
| | Motion | 1 | 2012 | 94 | 0.090 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2021 | 928 | 0.090 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 4 | 2024 | 973 | 0.090 |
Why?
| | Hypopituitarism | 1 | 2011 | 16 | 0.090 |
Why?
| | Arthritis, Rheumatoid | 1 | 2020 | 1184 | 0.090 |
Why?
| | Immunity, Innate | 2 | 2025 | 843 | 0.090 |
Why?
| | Otx Transcription Factors | 1 | 2011 | 15 | 0.080 |
Why?
| | Brucella suis | 1 | 2011 | 1 | 0.080 |
Why?
| | Brucellosis | 1 | 2011 | 2 | 0.080 |
Why?
| | Heme | 1 | 2012 | 90 | 0.080 |
Why?
| | Regulatory Sequences, Nucleic Acid | 2 | 2017 | 90 | 0.080 |
Why?
| | Caspase 2 | 1 | 2011 | 12 | 0.080 |
Why?
| | Gene Expression Regulation, Viral | 1 | 2011 | 92 | 0.080 |
Why?
| | Cattle | 1 | 2014 | 938 | 0.080 |
Why?
| | Electronic Health Records | 1 | 2020 | 1208 | 0.080 |
Why?
| | Prostatic Intraepithelial Neoplasia | 2 | 2008 | 9 | 0.080 |
Why?
| | Immunoglobulin G | 2 | 2026 | 899 | 0.080 |
Why?
| | Real-Time Polymerase Chain Reaction | 2 | 2022 | 333 | 0.080 |
Why?
| | MicroRNAs | 1 | 2017 | 695 | 0.080 |
Why?
| | Chemoradiotherapy | 3 | 2017 | 238 | 0.080 |
Why?
| | Catalytic Domain | 1 | 2012 | 234 | 0.080 |
Why?
| | Lipid Bilayers | 1 | 2012 | 104 | 0.080 |
Why?
| | Pharmacogenetics | 1 | 2012 | 176 | 0.080 |
Why?
| | Chemokines | 1 | 2011 | 217 | 0.080 |
Why?
| | Neoplasm Invasiveness | 4 | 2017 | 503 | 0.080 |
Why?
| | Lung | 2 | 2023 | 4119 | 0.080 |
Why?
| | Stress Disorders, Post-Traumatic | 2 | 2019 | 889 | 0.080 |
Why?
| | Pediatrics | 1 | 2019 | 1122 | 0.080 |
Why?
| | Vaccination | 1 | 2019 | 1444 | 0.080 |
Why?
| | Zalcitabine | 1 | 2010 | 2 | 0.080 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2011 | 161 | 0.080 |
Why?
| | Didanosine | 1 | 2010 | 13 | 0.080 |
Why?
| | Nonlinear Dynamics | 1 | 2010 | 95 | 0.080 |
Why?
| | Oxidation-Reduction | 1 | 2014 | 1075 | 0.080 |
Why?
| | Mental Disorders | 1 | 2019 | 1133 | 0.080 |
Why?
| | Phosphoglycerate Kinase | 1 | 2009 | 2 | 0.070 |
Why?
| | Antibody Formation | 2 | 2007 | 290 | 0.070 |
Why?
| | Activities of Daily Living | 2 | 2003 | 438 | 0.070 |
Why?
| | Sarcosine | 1 | 2009 | 10 | 0.070 |
Why?
| | Decision Trees | 2 | 2020 | 75 | 0.070 |
Why?
| | Autoimmunity | 2 | 2025 | 924 | 0.070 |
Why?
| | Rural Population | 1 | 2014 | 673 | 0.070 |
Why?
| | Delivery of Health Care | 1 | 2016 | 942 | 0.070 |
Why?
| | CpG Islands | 2 | 2023 | 175 | 0.070 |
Why?
| | Retinitis Pigmentosa | 1 | 2008 | 21 | 0.070 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 2010 | 130 | 0.070 |
Why?
| | Peptide Library | 2 | 2007 | 91 | 0.070 |
Why?
| | Genes, Recessive | 1 | 2008 | 77 | 0.070 |
Why?
| | Acculturation | 1 | 2008 | 55 | 0.070 |
Why?
| | Homozygote | 1 | 2008 | 196 | 0.070 |
Why?
| | Psoriasis | 1 | 2009 | 110 | 0.070 |
Why?
| | Complex Mixtures | 1 | 2007 | 11 | 0.070 |
Why?
| | Retrospective Studies | 6 | 2024 | 17291 | 0.070 |
Why?
| | Receptors, Adrenergic, beta-2 | 1 | 2007 | 36 | 0.070 |
Why?
| | Models, Molecular | 2 | 2019 | 1571 | 0.070 |
Why?
| | Mice, Nude | 2 | 2021 | 665 | 0.060 |
Why?
| | Confidence Intervals | 1 | 2008 | 328 | 0.060 |
Why?
| | Blindness | 1 | 2008 | 51 | 0.060 |
Why?
| | Uncertainty | 1 | 2008 | 145 | 0.060 |
Why?
| | Xenopus | 1 | 2007 | 85 | 0.060 |
Why?
| | Proteins | 2 | 2003 | 1021 | 0.060 |
Why?
| | Anti-HIV Agents | 1 | 2015 | 914 | 0.060 |
Why?
| | Glaucoma | 1 | 2010 | 253 | 0.060 |
Why?
| | Leisure Activities | 1 | 2007 | 31 | 0.060 |
Why?
| | Respiratory Tract Infections | 1 | 2011 | 399 | 0.060 |
Why?
| | Genes, myc | 1 | 2007 | 45 | 0.060 |
Why?
| | Pituitary Neoplasms | 1 | 2009 | 190 | 0.060 |
Why?
| | Antibodies, Neoplasm | 1 | 2007 | 34 | 0.060 |
Why?
| | Decision Theory | 1 | 2006 | 2 | 0.060 |
Why?
| | Lymphatic Metastasis | 2 | 2019 | 335 | 0.060 |
Why?
| | Genome, Bacterial | 2 | 2006 | 122 | 0.060 |
Why?
| | Nails | 1 | 2007 | 14 | 0.060 |
Why?
| | Self Concept | 1 | 2009 | 257 | 0.060 |
Why?
| | Practice Patterns, Physicians' | 1 | 2016 | 1370 | 0.060 |
Why?
| | Alcohol Dehydrogenase | 1 | 2026 | 21 | 0.060 |
Why?
| | Socioeconomic Factors | 2 | 2008 | 1323 | 0.060 |
Why?
| | Information Storage and Retrieval | 1 | 2007 | 121 | 0.060 |
Why?
| | Nepal | 2 | 2016 | 31 | 0.060 |
Why?
| | Genome, Human | 4 | 2016 | 425 | 0.060 |
Why?
| | Genetic Pleiotropy | 1 | 2026 | 36 | 0.060 |
Why?
| | Enzyme-Linked Immunospot Assay | 1 | 2026 | 40 | 0.060 |
Why?
| | Genes, MHC Class II | 1 | 2006 | 77 | 0.060 |
Why?
| | DNA, Bacterial | 2 | 2006 | 319 | 0.060 |
Why?
| | Pharynx | 1 | 2006 | 60 | 0.060 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2023 | 3930 | 0.060 |
Why?
| | Apoptosis | 3 | 2021 | 2436 | 0.060 |
Why?
| | Haemophilus Infections | 1 | 2006 | 45 | 0.060 |
Why?
| | Serine Endopeptidases | 1 | 2007 | 129 | 0.060 |
Why?
| | Arsenic | 1 | 2007 | 66 | 0.060 |
Why?
| | Haemophilus influenzae | 1 | 2006 | 67 | 0.060 |
Why?
| | Structure-Activity Relationship | 1 | 2007 | 561 | 0.060 |
Why?
| | Washington | 1 | 2026 | 157 | 0.060 |
Why?
| | GATA3 Transcription Factor | 1 | 2005 | 22 | 0.060 |
Why?
| | Death Certificates | 1 | 2006 | 32 | 0.060 |
Why?
| | Calibration | 2 | 2022 | 154 | 0.060 |
Why?
| | Biotinylation | 1 | 2005 | 37 | 0.060 |
Why?
| | Cell Cycle Proteins | 2 | 2007 | 629 | 0.060 |
Why?
| | Molecular Mimicry | 1 | 2005 | 36 | 0.060 |
Why?
| | Nephrocalcinosis | 1 | 2025 | 12 | 0.060 |
Why?
| | Antibodies, Anti-Idiotypic | 1 | 2005 | 50 | 0.060 |
Why?
| | Quantitative Trait Loci | 1 | 2008 | 388 | 0.060 |
Why?
| | Frail Elderly | 1 | 2026 | 136 | 0.060 |
Why?
| | Hydrogen Bonding | 1 | 2005 | 170 | 0.060 |
Why?
| | STAT5 Transcription Factor | 1 | 2025 | 50 | 0.060 |
Why?
| | Chromosomes, Human, Pair 17 | 1 | 2005 | 54 | 0.060 |
Why?
| | Diabetic Retinopathy | 1 | 2008 | 211 | 0.060 |
Why?
| | Environmental Pollutants | 1 | 2007 | 142 | 0.050 |
Why?
| | Absorptiometry, Photon | 1 | 2026 | 276 | 0.050 |
Why?
| | United States | 7 | 2018 | 16041 | 0.050 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2005 | 382 | 0.050 |
Why?
| | Protein Interaction Mapping | 1 | 2005 | 105 | 0.050 |
Why?
| | Family Characteristics | 2 | 2016 | 202 | 0.050 |
Why?
| | Interleukin-15 | 1 | 2025 | 96 | 0.050 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 1 | 2005 | 61 | 0.050 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2006 | 365 | 0.050 |
Why?
| | Asthma | 2 | 2007 | 1800 | 0.050 |
Why?
| | Disease-Free Survival | 3 | 2017 | 777 | 0.050 |
Why?
| | Area Under Curve | 2 | 2020 | 333 | 0.050 |
Why?
| | Mobile Health Units | 1 | 2024 | 21 | 0.050 |
Why?
| | Protein Structure, Secondary | 1 | 2005 | 357 | 0.050 |
Why?
| | Polymerase Chain Reaction | 3 | 2017 | 1030 | 0.050 |
Why?
| | Poisson Distribution | 1 | 2004 | 77 | 0.050 |
Why?
| | Retinal Rod Photoreceptor Cells | 1 | 2004 | 17 | 0.050 |
Why?
| | Linkage Disequilibrium | 1 | 2005 | 257 | 0.050 |
Why?
| | Retinal Cone Photoreceptor Cells | 1 | 2004 | 20 | 0.050 |
Why?
| | Sputum | 1 | 2006 | 302 | 0.050 |
Why?
| | Bed Occupancy | 1 | 2024 | 16 | 0.050 |
Why?
| | Granulomatous Disease, Chronic | 1 | 2004 | 49 | 0.050 |
Why?
| | Environmental Monitoring | 1 | 2007 | 346 | 0.050 |
Why?
| | Geriatric Assessment | 1 | 2026 | 238 | 0.050 |
Why?
| | Triglycerides | 1 | 2026 | 527 | 0.050 |
Why?
| | Culture Techniques | 1 | 2004 | 65 | 0.050 |
Why?
| | Fluorescent Antibody Technique | 2 | 2020 | 345 | 0.050 |
Why?
| | Bacterial Typing Techniques | 1 | 2004 | 40 | 0.050 |
Why?
| | Cancer Vaccines | 1 | 2005 | 161 | 0.050 |
Why?
| | Gallium Radioisotopes | 1 | 2023 | 16 | 0.050 |
Why?
| | Pedigree | 2 | 2019 | 507 | 0.050 |
Why?
| | Serotonin Plasma Membrane Transport Proteins | 1 | 2004 | 61 | 0.050 |
Why?
| | Lipids | 1 | 2009 | 715 | 0.050 |
Why?
| | Genetic Heterogeneity | 1 | 2004 | 66 | 0.050 |
Why?
| | Polybrominated Biphenyls | 1 | 2003 | 2 | 0.050 |
Why?
| | Body Mass Index | 2 | 2016 | 2446 | 0.050 |
Why?
| | Antigens, Neoplasm | 1 | 2005 | 271 | 0.050 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2009 | 899 | 0.050 |
Why?
| | Fatigue | 1 | 2026 | 362 | 0.050 |
Why?
| | Otitis Media | 1 | 2006 | 178 | 0.050 |
Why?
| | Personality Inventory | 1 | 2004 | 132 | 0.050 |
Why?
| | Radionuclide Imaging | 1 | 2023 | 116 | 0.050 |
Why?
| | Genetics, Population | 1 | 2005 | 225 | 0.050 |
Why?
| | Pandemics | 2 | 2023 | 1700 | 0.050 |
Why?
| | Immunophenotyping | 2 | 2020 | 324 | 0.050 |
Why?
| | Expressed Sequence Tags | 1 | 2003 | 43 | 0.050 |
Why?
| | Cause of Death | 1 | 2006 | 455 | 0.050 |
Why?
| | Wnt Proteins | 2 | 2020 | 131 | 0.050 |
Why?
| | Signal-To-Noise Ratio | 1 | 2023 | 71 | 0.050 |
Why?
| | Down-Regulation | 1 | 2025 | 612 | 0.050 |
Why?
| | Bile Ducts | 1 | 2003 | 65 | 0.050 |
Why?
| | Immunoglobulin M | 1 | 2024 | 284 | 0.050 |
Why?
| | GTPase-Activating Proteins | 1 | 2023 | 81 | 0.050 |
Why?
| | T-Lymphocytes, Helper-Inducer | 1 | 2023 | 127 | 0.050 |
Why?
| | Residence Characteristics | 1 | 2026 | 385 | 0.050 |
Why?
| | Hyperplasia | 1 | 2003 | 164 | 0.050 |
Why?
| | Antibodies, Monoclonal | 2 | 2012 | 1511 | 0.050 |
Why?
| | Macrophages | 1 | 2011 | 1530 | 0.050 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2021 | 845 | 0.050 |
Why?
| | Artifacts | 1 | 2023 | 142 | 0.050 |
Why?
| | Health Policy | 1 | 2026 | 399 | 0.050 |
Why?
| | Breast | 1 | 2003 | 154 | 0.050 |
Why?
| | Biological Specimen Banks | 1 | 2024 | 137 | 0.050 |
Why?
| | Biguanides | 1 | 2022 | 10 | 0.050 |
Why?
| | Motor Activity | 1 | 2007 | 701 | 0.050 |
Why?
| | Selection Bias | 1 | 2022 | 38 | 0.050 |
Why?
| | Receptors, Antigen, B-Cell | 1 | 2023 | 133 | 0.050 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2026 | 1403 | 0.050 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2023 | 143 | 0.050 |
Why?
| | Calcium Signaling | 1 | 2004 | 246 | 0.050 |
Why?
| | Sarcoma, Ewing | 1 | 2003 | 103 | 0.040 |
Why?
| | Killer Cells, Natural | 1 | 2025 | 481 | 0.040 |
Why?
| | Membrane Proteins | 1 | 2008 | 1130 | 0.040 |
Why?
| | Complement System Proteins | 1 | 2005 | 324 | 0.040 |
Why?
| | Dendritic Cells | 1 | 2025 | 507 | 0.040 |
Why?
| | Benchmarking | 1 | 2023 | 192 | 0.040 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2025 | 411 | 0.040 |
Why?
| | Genes, BRCA2 | 1 | 2002 | 33 | 0.040 |
Why?
| | Yeasts | 1 | 2002 | 54 | 0.040 |
Why?
| | Evaluation Studies as Topic | 1 | 2002 | 160 | 0.040 |
Why?
| | Lymphoma, B-Cell | 1 | 2003 | 149 | 0.040 |
Why?
| | Hospitalization | 2 | 2024 | 2468 | 0.040 |
Why?
| | Mice, Inbred C57BL | 2 | 2025 | 6021 | 0.040 |
Why?
| | Genes, BRCA1 | 1 | 2002 | 45 | 0.040 |
Why?
| | Faculty, Medical | 1 | 2025 | 305 | 0.040 |
Why?
| | Seasons | 1 | 2024 | 535 | 0.040 |
Why?
| | Epithelial Cells | 2 | 2008 | 1118 | 0.040 |
Why?
| | T-Lymphocyte Subsets | 1 | 2023 | 415 | 0.040 |
Why?
| | Antigens, Protozoan | 1 | 2021 | 32 | 0.040 |
Why?
| | Health Care Surveys | 2 | 2016 | 538 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2005 | 2018 | 0.040 |
Why?
| | Evolution, Molecular | 1 | 2005 | 501 | 0.040 |
Why?
| | Citrullination | 1 | 2020 | 12 | 0.040 |
Why?
| | Japan | 1 | 2021 | 149 | 0.040 |
Why?
| | Genetic Testing | 1 | 2004 | 491 | 0.040 |
Why?
| | Somatostatin-Secreting Cells | 1 | 2020 | 2 | 0.040 |
Why?
| | Leadership | 1 | 2025 | 410 | 0.040 |
Why?
| | Drosophila Proteins | 1 | 2002 | 207 | 0.040 |
Why?
| | Receptors, Retinoic Acid | 1 | 2020 | 43 | 0.040 |
Why?
| | Milk, Human | 1 | 2022 | 176 | 0.040 |
Why?
| | Somatostatin | 1 | 2020 | 54 | 0.040 |
Why?
| | Human Embryonic Stem Cells | 1 | 2020 | 24 | 0.040 |
Why?
| | Immunity, Cellular | 1 | 2022 | 277 | 0.040 |
Why?
| | Citalopram | 1 | 2020 | 33 | 0.040 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2022 | 507 | 0.040 |
Why?
| | Policy | 1 | 2021 | 147 | 0.040 |
Why?
| | Surveys and Questionnaires | 2 | 2026 | 6050 | 0.040 |
Why?
| | Leukocytes, Mononuclear | 1 | 2023 | 585 | 0.040 |
Why?
| | Support Vector Machine | 1 | 2020 | 33 | 0.040 |
Why?
| | Nutrition Surveys | 1 | 2021 | 270 | 0.040 |
Why?
| | Polycomb Repressive Complex 2 | 3 | 2007 | 79 | 0.040 |
Why?
| | Embryo, Mammalian | 1 | 2020 | 230 | 0.040 |
Why?
| | Immunoblotting | 3 | 2005 | 294 | 0.040 |
Why?
| | Alcohol Drinking | 1 | 2026 | 847 | 0.040 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2023 | 676 | 0.040 |
Why?
| | Allosteric Regulation | 1 | 2019 | 100 | 0.040 |
Why?
| | International Classification of Diseases | 1 | 2020 | 142 | 0.040 |
Why?
| | Nanog Homeobox Protein | 1 | 2019 | 12 | 0.040 |
Why?
| | Disease Vectors | 1 | 2019 | 15 | 0.040 |
Why?
| | Polymethyl Methacrylate | 1 | 2019 | 21 | 0.040 |
Why?
| | Skin | 2 | 2017 | 701 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2020 | 339 | 0.040 |
Why?
| | Cognition Disorders | 1 | 2003 | 547 | 0.040 |
Why?
| | Binding Sites | 2 | 2017 | 1306 | 0.040 |
Why?
| | Leprosy | 1 | 2019 | 25 | 0.040 |
Why?
| | Schizophrenic Psychology | 1 | 2019 | 100 | 0.040 |
Why?
| | Interferon-gamma | 1 | 2022 | 780 | 0.030 |
Why?
| | Quality of Life | 2 | 2009 | 3187 | 0.030 |
Why?
| | Disease Models, Animal | 2 | 2025 | 4565 | 0.030 |
Why?
| | Breast Feeding | 1 | 2022 | 447 | 0.030 |
Why?
| | SEER Program | 1 | 2019 | 233 | 0.030 |
Why?
| | Virulence | 2 | 2011 | 287 | 0.030 |
Why?
| | Electroencephalography | 1 | 2021 | 570 | 0.030 |
Why?
| | B-Lymphocytes | 1 | 2023 | 884 | 0.030 |
Why?
| | Mice, SCID | 1 | 2019 | 360 | 0.030 |
Why?
| | Epigenesis, Genetic | 2 | 2017 | 705 | 0.030 |
Why?
| | Malaria | 1 | 2019 | 73 | 0.030 |
Why?
| | Prostatic Hyperplasia | 2 | 2008 | 40 | 0.030 |
Why?
| | Autoantigens | 1 | 2020 | 426 | 0.030 |
Why?
| | Inflammation Mediators | 1 | 2020 | 507 | 0.030 |
Why?
| | Xenodiagnosis | 1 | 2017 | 2 | 0.030 |
Why?
| | Adjuvants, Immunologic | 1 | 2019 | 243 | 0.030 |
Why?
| | Protein Domains | 1 | 2019 | 314 | 0.030 |
Why?
| | DNA, Protozoan | 1 | 2017 | 32 | 0.030 |
Why?
| | Protein Stability | 1 | 2018 | 175 | 0.030 |
Why?
| | Kidney | 1 | 2025 | 1491 | 0.030 |
Why?
| | Seizures | 1 | 2021 | 489 | 0.030 |
Why?
| | Mice, Knockout | 2 | 2020 | 3121 | 0.030 |
Why?
| | National Cancer Institute (U.S.) | 1 | 2017 | 55 | 0.030 |
Why?
| | Mice, Inbred NOD | 1 | 2019 | 598 | 0.030 |
Why?
| | Taiwan | 2 | 2007 | 48 | 0.030 |
Why?
| | Databases, Protein | 2 | 2007 | 88 | 0.030 |
Why?
| | Michigan | 2 | 2007 | 134 | 0.030 |
Why?
| | Tissue Scaffolds | 1 | 2019 | 220 | 0.030 |
Why?
| | Enzyme Stability | 1 | 2016 | 74 | 0.030 |
Why?
| | After-Hours Care | 1 | 2016 | 16 | 0.030 |
Why?
| | Sterilization, Tubal | 1 | 2016 | 17 | 0.030 |
Why?
| | Analgesia, Patient-Controlled | 1 | 2016 | 18 | 0.030 |
Why?
| | Population Density | 1 | 2016 | 90 | 0.030 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2017 | 143 | 0.030 |
Why?
| | Platelet Count | 1 | 2016 | 94 | 0.030 |
Why?
| | Fibroblasts | 1 | 2002 | 1033 | 0.030 |
Why?
| | Prostate | 2 | 2008 | 159 | 0.030 |
Why?
| | Live Birth | 1 | 2016 | 81 | 0.030 |
Why?
| | Prostate-Specific Antigen | 2 | 2008 | 162 | 0.030 |
Why?
| | Enzyme Inhibitors | 1 | 2019 | 820 | 0.030 |
Why?
| | International Cooperation | 1 | 2016 | 192 | 0.030 |
Why?
| | Enhancer of Zeste Homolog 2 Protein | 2 | 2007 | 55 | 0.030 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2016 | 100 | 0.030 |
Why?
| | Survivors | 1 | 2019 | 521 | 0.030 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2017 | 429 | 0.030 |
Why?
| | Amino Acid Substitution | 1 | 2016 | 295 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2018 | 746 | 0.030 |
Why?
| | Tuberculosis | 1 | 2019 | 289 | 0.030 |
Why?
| | Cholesterol, HDL | 1 | 2016 | 201 | 0.030 |
Why?
| | Genes, Bacterial | 2 | 2006 | 151 | 0.030 |
Why?
| | Family | 1 | 2019 | 680 | 0.030 |
Why?
| | Rats | 1 | 2003 | 5574 | 0.030 |
Why?
| | Cell Movement | 1 | 2019 | 950 | 0.030 |
Why?
| | Gene Regulatory Networks | 2 | 2007 | 319 | 0.030 |
Why?
| | Epistasis, Genetic | 1 | 2015 | 66 | 0.030 |
Why?
| | Skin Neoplasms | 1 | 2002 | 805 | 0.030 |
Why?
| | Cognition | 1 | 2003 | 1286 | 0.030 |
Why?
| | Cardiovascular System | 1 | 2016 | 137 | 0.030 |
Why?
| | Genes, Essential | 1 | 2014 | 19 | 0.030 |
Why?
| | Particulate Matter | 1 | 2017 | 328 | 0.030 |
Why?
| | Neuropsychological Tests | 1 | 2019 | 1136 | 0.030 |
Why?
| | Cesarean Section | 1 | 2016 | 229 | 0.030 |
Why?
| | GATA1 Transcription Factor | 1 | 2014 | 18 | 0.030 |
Why?
| | Occupational Exposure | 1 | 2018 | 356 | 0.030 |
Why?
| | Data Collection | 2 | 2007 | 647 | 0.030 |
Why?
| | Molecular Sequence Annotation | 1 | 2014 | 110 | 0.030 |
Why?
| | Hospitals, Public | 1 | 2013 | 30 | 0.020 |
Why?
| | Demography | 1 | 2014 | 274 | 0.020 |
Why?
| | North America | 1 | 2014 | 299 | 0.020 |
Why?
| | Methylation | 1 | 2014 | 241 | 0.020 |
Why?
| | Receptors, Estrogen | 2 | 2007 | 405 | 0.020 |
Why?
| | Organ Specificity | 1 | 2014 | 306 | 0.020 |
Why?
| | Hospitals, Rural | 1 | 2013 | 49 | 0.020 |
Why?
| | Host-Parasite Interactions | 1 | 2014 | 109 | 0.020 |
Why?
| | Species Specificity | 1 | 2014 | 542 | 0.020 |
Why?
| | Gene-Environment Interaction | 1 | 2014 | 188 | 0.020 |
Why?
| | Cell Line | 2 | 2009 | 2809 | 0.020 |
Why?
| | RNA Processing, Post-Transcriptional | 1 | 2013 | 92 | 0.020 |
Why?
| | Sequence Analysis, DNA | 2 | 2006 | 771 | 0.020 |
Why?
| | Cytokines | 1 | 2020 | 2079 | 0.020 |
Why?
| | Schizosaccharomyces | 1 | 2013 | 85 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2013 | 429 | 0.020 |
Why?
| | Methane | 1 | 2012 | 45 | 0.020 |
Why?
| | Hydrogen | 1 | 2012 | 73 | 0.020 |
Why?
| | Cetuximab | 1 | 2012 | 110 | 0.020 |
Why?
| | Databases, Nucleic Acid | 1 | 2012 | 39 | 0.020 |
Why?
| | Carboplatin | 1 | 2012 | 168 | 0.020 |
Why?
| | Emergency Service, Hospital | 1 | 2024 | 2357 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2013 | 782 | 0.020 |
Why?
| | Paclitaxel | 1 | 2012 | 258 | 0.020 |
Why?
| | In Situ Hybridization | 1 | 2011 | 317 | 0.020 |
Why?
| | Quinazolines | 1 | 2012 | 267 | 0.020 |
Why?
| | Prospective Studies | 3 | 2009 | 8087 | 0.020 |
Why?
| | Self Report | 1 | 2014 | 869 | 0.020 |
Why?
| | Mass Screening | 1 | 2018 | 1300 | 0.020 |
Why?
| | Electrophoresis | 1 | 2009 | 31 | 0.020 |
Why?
| | Pituitary Hormones | 1 | 2009 | 15 | 0.020 |
Why?
| | Hospitals | 1 | 2014 | 730 | 0.020 |
Why?
| | Cell Death | 1 | 2011 | 379 | 0.020 |
Why?
| | Sarcosine Dehydrogenase | 1 | 2009 | 1 | 0.020 |
Why?
| | Glycine N-Methyltransferase | 1 | 2009 | 4 | 0.020 |
Why?
| | Bone Morphogenetic Protein Receptors, Type I | 1 | 2009 | 10 | 0.020 |
Why?
| | Depression | 1 | 2019 | 1566 | 0.020 |
Why?
| | Blood Pressure | 1 | 2016 | 1761 | 0.020 |
Why?
| | Insulin | 1 | 2020 | 2524 | 0.020 |
Why?
| | Ophthalmoscopy | 1 | 2008 | 38 | 0.020 |
Why?
| | Interleukin-1beta | 1 | 2011 | 394 | 0.020 |
Why?
| | Electroretinography | 1 | 2008 | 51 | 0.020 |
Why?
| | Consanguinity | 1 | 2008 | 50 | 0.020 |
Why?
| | Mice, Mutant Strains | 1 | 2009 | 290 | 0.020 |
Why?
| | Gene Library | 1 | 2009 | 121 | 0.020 |
Why?
| | Gene Expression Regulation, Bacterial | 1 | 2011 | 337 | 0.020 |
Why?
| | Golgi Apparatus | 1 | 2008 | 98 | 0.020 |
Why?
| | Antineoplastic Agents | 2 | 2012 | 2218 | 0.020 |
Why?
| | Keratinocytes | 1 | 2009 | 190 | 0.020 |
Why?
| | Genes | 1 | 2008 | 215 | 0.020 |
Why?
| | Chemical Fractionation | 1 | 2007 | 29 | 0.020 |
Why?
| | Gene Knockdown Techniques | 1 | 2009 | 334 | 0.020 |
Why?
| | Chromosomes, Human, 16-18 | 1 | 2007 | 3 | 0.020 |
Why?
| | Chromosomes, Human, 6-12 and X | 1 | 2007 | 3 | 0.020 |
Why?
| | DNA Primers | 1 | 2008 | 487 | 0.020 |
Why?
| | Polycomb-Group Proteins | 1 | 2007 | 36 | 0.020 |
Why?
| | Chromosomes, Human, Pair 5 | 1 | 2007 | 30 | 0.020 |
Why?
| | Chromosomes, Human, Pair 3 | 1 | 2007 | 43 | 0.020 |
Why?
| | Feedback | 1 | 2008 | 180 | 0.020 |
Why?
| | Bacteriophage T7 | 1 | 2007 | 5 | 0.020 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 1996 | 0.020 |
Why?
| | Neoplasm Transplantation | 1 | 2007 | 238 | 0.020 |
Why?
| | Seaweed | 1 | 2007 | 1 | 0.020 |
Why?
| | Agaricales | 1 | 2007 | 3 | 0.020 |
Why?
| | Chromatography, Liquid | 1 | 2009 | 452 | 0.020 |
Why?
| | Models, Animal | 1 | 2009 | 386 | 0.020 |
Why?
| | Subtraction Technique | 1 | 2007 | 26 | 0.020 |
Why?
| | Data Display | 1 | 2007 | 20 | 0.020 |
Why?
| | Autophagy-Related Proteins | 1 | 2007 | 46 | 0.020 |
Why?
| | Chromosomes, Human | 1 | 2007 | 45 | 0.020 |
Why?
| | Seafood | 1 | 2007 | 25 | 0.020 |
Why?
| | Food Contamination | 1 | 2007 | 36 | 0.020 |
Why?
| | Oxidative Stress | 1 | 2013 | 1367 | 0.020 |
Why?
| | Television | 1 | 2007 | 70 | 0.020 |
Why?
| | Oryza | 1 | 2007 | 33 | 0.020 |
Why?
| | Sequence Analysis, Protein | 1 | 2006 | 32 | 0.020 |
Why?
| | Oxygen | 1 | 2012 | 996 | 0.020 |
Why?
| | Inhibitory Concentration 50 | 1 | 2006 | 90 | 0.020 |
Why?
| | Tomography, Optical Coherence | 1 | 2008 | 277 | 0.020 |
Why?
| | Managed Care Programs | 1 | 2007 | 137 | 0.010 |
Why?
| | Fishes | 1 | 2007 | 111 | 0.010 |
Why?
| | Nucleic Acid Hybridization | 1 | 2006 | 175 | 0.010 |
Why?
| | Lymphoma | 1 | 2008 | 251 | 0.010 |
Why?
| | Ear, Middle | 1 | 2006 | 78 | 0.010 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2013 | 1148 | 0.010 |
Why?
| | Water Supply | 1 | 2007 | 90 | 0.010 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2011 | 1223 | 0.010 |
Why?
| | Urban Health | 1 | 2006 | 95 | 0.010 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2012 | 992 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 2009 | 1361 | 0.010 |
Why?
| | Drug Design | 1 | 2007 | 179 | 0.010 |
Why?
| | Fibrocystic Breast Disease | 1 | 2005 | 2 | 0.010 |
Why?
| | Lipid Metabolism | 1 | 2009 | 533 | 0.010 |
Why?
| | Databases as Topic | 1 | 2005 | 70 | 0.010 |
Why?
| | Base Composition | 1 | 2005 | 81 | 0.010 |
Why?
| | E2F Transcription Factors | 1 | 2005 | 65 | 0.010 |
Why?
| | Oligonucleotide Probes | 1 | 2005 | 48 | 0.010 |
Why?
| | DNA Probes | 1 | 2005 | 57 | 0.010 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2007 | 384 | 0.010 |
Why?
| | Neoplasms, Hormone-Dependent | 1 | 2004 | 33 | 0.010 |
Why?
| | Bone Morphogenetic Protein Receptors | 1 | 2004 | 5 | 0.010 |
Why?
| | Autopsy | 1 | 2004 | 96 | 0.010 |
Why?
| | Smad Proteins | 1 | 2004 | 42 | 0.010 |
Why?
| | Receptors, Growth Factor | 1 | 2004 | 52 | 0.010 |
Why?
| | Basic-Leucine Zipper Transcription Factors | 1 | 2004 | 43 | 0.010 |
Why?
| | Receptors, Progesterone | 1 | 2005 | 241 | 0.010 |
Why?
| | Random Allocation | 1 | 2005 | 365 | 0.010 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2007 | 427 | 0.010 |
Why?
| | Recombination, Genetic | 1 | 2005 | 202 | 0.010 |
Why?
| | Oligonucleotides | 1 | 2004 | 154 | 0.010 |
Why?
| | Retinal Diseases | 1 | 2004 | 101 | 0.010 |
Why?
| | Selection, Genetic | 1 | 2005 | 269 | 0.010 |
Why?
| | Spermine | 1 | 2002 | 29 | 0.010 |
Why?
| | Spermidine | 1 | 2002 | 18 | 0.010 |
Why?
| | Genes, Tumor Suppressor | 1 | 2002 | 84 | 0.010 |
Why?
| | Internet | 1 | 2007 | 656 | 0.010 |
Why?
| | Overweight | 1 | 2007 | 613 | 0.010 |
Why?
| | Cell Cycle | 1 | 2004 | 595 | 0.010 |
Why?
| | Adenosine Monophosphate | 1 | 2002 | 87 | 0.010 |
Why?
| | Biopsy, Needle | 1 | 2002 | 182 | 0.010 |
Why?
| | California | 1 | 2003 | 473 | 0.010 |
Why?
| | Mental Recall | 1 | 2003 | 224 | 0.010 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2003 | 512 | 0.010 |
Why?
| | Proto-Oncogene Proteins | 1 | 2004 | 615 | 0.010 |
Why?
| | Comorbidity | 1 | 2006 | 1652 | 0.010 |
Why?
| | Transfection | 1 | 2002 | 914 | 0.010 |
Why?
| | Bacterial Proteins | 1 | 2006 | 976 | 0.010 |
Why?
| | RNA | 1 | 2005 | 925 | 0.010 |
Why?
| | Predictive Value of Tests | 1 | 2002 | 2097 | 0.010 |
Why?
| | Stroke | 1 | 2003 | 1283 | 0.010 |
Why?
| | Aging | 1 | 2003 | 1983 | 0.010 |
Why?
|
|
Ghosh's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|